Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
A FIVEFOLD price hike for EpiPen, which allergy sufferers use to counteract life-threatening reactions, has made Mylan the newest drugmaker to come under attack in the United States for profiteering.
Mylan Pharmaceuticals, which holds a near-monopoly position on the